Amicus Therapeutics Inc at UBS BioPharma Conference Transcript
Good afternoon, everyone. I'm Ellie Merle, one of the biotech analysts here at UBS. Thank you so much for joining us here at the UBS Biopharma Conference in Miami. Very happy to have Amicus Therapeutics here with us today for a fireside chat.
Joining us from Amicus is Jeff Castelli, Chief Development Officer. Thanks so much for making the trip to Miami. Maybe just to kick it off, you guys reported earnings yesterday, including first sales in Pompe. So talk a little bit about that.
Yes. Thank you, Ellie. Thanks to the UBS team for having us. We're happy to be here. Yes, we just had third quarter earnings yesterday. Very excited to give an update on the launch of Pombiliti and Opfolda in Pompe. As a reminder, we just recently received approval in July in Europe, in August in the U.K. and here at the end of September in the U.S. And I'm really excited by early days of launch. We said that we're well on track to
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |